Empagliflozin to Be Investigated in Chronic Kidney Disease

Jardiance is currently approved as adjunct to diet and exercise to improve glycemic control in adults with T2D
Jardiance is currently approved as adjunct to diet and exercise to improve glycemic control in adults with T2D

Boehringer Ingelheim and Lilly announced that a new clinical trial is being planned to evaluate Jardiance (empagliflozin) tablets for the treatment of patients with chronic kidney disease (CKD) both with and without type 2 diabetes.  In addition, the companies are conducting other mechanistic studies that will evaluate the potential mechanisms by which empagliflozin may affect renal outcomes in patients with CKD (i.e., decreasing glomerular pressure).

Jardiance, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, is currently approved as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of cardiovascular (CV) death in adults with type 2 diabetes mellitus and established CV disease. 

Related Articles

In the EMPA-REG OUTCOME trial (n>7,000), Jardiance was found to lower the risk for new-onset or worsening of kidney disease by 39% vs. placebo when added to standard of care in adults with type 2 diabetes and established cardiovascular disease. Standard of care included glucose-lowering agents and cardiovascular agents. The trial was not intended to assess empagliflozin mechanisms on renal outcomes but the kidney assessment was part of a pre-specified exploratory analysis of additional endpoints.

Jardiance is available as 10mg and 25mg strength tablets in 30- and 90-count bottles.

For more information call (800) 243-0127 or visit Jardiance.com.